Is Sanofi making a move into obesity? French pharma invests $27M into Ventyx
For the past few years, Sanofi has stayed out of the obesity drug development bonanza, taking a wait-and-see approach while keeping an eye on potential …
Sign up to read this article for free.
Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.
